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Introduction
The finding that successful antiretroviral therapy (ART)
can almost eliminate the risk of heterosexual HIV trans-
mission is the scientific breakthrough of 2011 according to
Science Magazine. This potential of ART has generated
novel approaches to prevention including “Test and Treat”
(T&T). Our qualitative study, drawing on the perspectives
of French HIV experts, aims to better understand if, and
how, a T&T approach might be applied in France and to
generally learn more about concerns raised by prevention
with early ART.
Materials and methods
In 2011, 19 French HIV experts participated in a semi-
structured interview on implementing T&T in France.
Expertise was typically defined on the basis of contribution
to the 2010 French ART guidelines (Rapport Yeni 2010).
Participants’ HIV expertise included clinical care, epide-
miology, virology, and community activism. Interviews
lasted an hour, on average, and explored opinions on
T&T, who, how and whether to test and treat, and what
public health discourses and evaluations should accom-
pany it. Analyses of interview content pertaining to who
or whether to treat early for prevention are presented
here. A content analysis of the transcribed interviews was
supported by the software Atlas.ti version 5.2.
Results
The decision to treat earlier than current guidelines
recommend (CD4 >500) was generally associated with
uncertainties and involved weighing the risks and bene-
fits, whether potential or known, primarily in terms of
patient health, the risk of transmission, patient choice,
population health and/or cost. Perspectives on each of
these aspects varied as did experts’ position on treating
early for prevention.
Conclusions
Despite ART-based HIV prevention’ss t a t u sa se v i d e n c e
based medicine (EBM), French experts had uncertainties
about early preventive treatment of HIV-infection which
often translated into a weighing of benefits and risks to
varying effect. Our findings suggest fostering a culture of
dialogue and debate between care providers, community
organizations and recipients of care on the complex con-
siderations of implementing strategies of ART as preven-
tion in France can help translate EBM into improvements
in health and new HIV guidelines towards the eradication
of HIV.
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